Form 4: PMV Pharmaceuticals CEO Exchanges Stock Options in Company Program
SEC Form 4 Filing
CEO David Henry Mack exchanged existing stock options for new options with a lower exercise price as part of PMV Pharmaceuticals' option exchange program.
Summary
- On August 13, 2024, David Henry Mack, the President and CEO of PMV Pharmaceuticals, participated in the company's option exchange program.
- Mack exchanged existing employee stock options for new options with an exercise price of $1.48 per share.
- Specifically, he exchanged options for 134,584 shares (originally granted on May 12, 2021, with an exercise price of $28.33), 249,600 shares (originally granted on February 10, 2022, with an exercise price of $16.29), and 330,000 shares (originally granted on May 12, 2023, with an exercise price of $5.70).
- In return, he received replacement options for the same number of shares (134,584, 249,600 and 330,000 respectively), all with an exercise price of $1.48 per share.
- The new options vest according to different schedules: one-third of the 384,184 shares vest on August 13, 2025, and then monthly; one-fourth of the 330,000 shares vest on August 13, 2025, and then monthly.
Sentiment
Score: 6
Explanation: The document describes a routine transaction. The sentiment is neutral as it reflects standard executive compensation practices.
Positives
- The option exchange program may incentivize the CEO by providing options with a more achievable exercise price.
Industry Context
Option exchange programs are sometimes used by companies to re-incentivize employees when the stock price has fallen significantly below the original option exercise price.
Stakeholder Impact
- The option exchange could potentially improve employee morale and motivation, aligning management's interests with shareholders.
Key Dates
| Date | Description |
|---|---|
| May 12, 2021 | Original grant date of options for 134,584 shares with an exercise price of $28.33. |
| June 12, 2021 | Vesting start date for the May 12, 2021 option grant. |
| February 10, 2022 | Original grant date of options for 249,600 shares with an exercise price of $16.29. |
| March 10, 2022 | Vesting start date for the February 10, 2022 option grant. |
| May 12, 2023 | Original grant date of options for 330,000 shares with an exercise price of $5.70. |
| June 12, 2023 | Vesting start date for the May 12, 2023 option grant. |
| August 13, 2024 | Date of the option exchange program transaction. |
| August 13, 2025 | Vesting start date for a portion of the new options granted in the exchange. |
| May 11, 2031 | Expiration date of the replacement option for 134,584 shares. |
| February 10, 2032 | Expiration date of the replacement option for 249,600 shares. |
| May 12, 2033 | Expiration date of the original option for 330,000 shares. |
| August 13, 2034 | Expiration date of the replacement option for 330,000 shares. |
| October 03, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.